CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cytochrome P-450 CYP3A
  • ErbB Receptors
  • Neoplasms
  • Protein Kinase Inhibitors
  • Quinazolines

abstract

  • As an in vivo phenotypic probe of CYP3A, midazolam oral clearance may have utility for prediction of gefitinib exposure and dose selection. A pharmacokinetic model incorporating this indicator of CYP3A activity has potential for optimization of treatment with gefitinib and other TK inhibitors that are metabolized in a similar manner.

publication date

  • December 6, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/jnci/djj466

PubMed ID

  • 17148773

Additional Document Info

start page

  • 1714

end page

  • 23

volume

  • 98

number

  • 23